DDD Partners
ALNY icon

DDD Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

DDD Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.1M Buy
16,602
+15,908
+2,292% +$4.05M 0.23% 59
2026
Q2 		$209K Sell
694
-195
-22% -$58.8K 0.01% 157
2026
Q1 		$294K Buy
+889
New +$303K 0.02% 115

Other funds holding ALNY

Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Antipodes Partners
Antipodes Partners Royal Exchange, Australia $5.43B AUM 15.86% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

DDD Partners's ALNY Position: Q3 2026 in Review

DDD Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 2,292% in Q3 2026, buying an estimated $4.05M and bringing the position to 16,602 shares worth $4.1M. The position accounts for 0.23% of the portfolio, ranked #59.

DDD Partners first reported a position in ALNY in Q1 2026 and has held it in 3 quarters since. 300 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • DDD Partners held 16,602 shares of Alnylam Pharmaceuticals worth $4.1M as of Q3 2026.
  • DDD Partners bought 15,908 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $4.05M.
  • Alnylam Pharmaceuticals made up 0.23% of DDD Partners's portfolio in Q3 2026, its #59 holding.
  • DDD Partners first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 300 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on DDD Partners's 13F filing for Q3 2026, filed 2 Nov 2026.